| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer, Director | C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO | /s/ Will Solis, Attorney-in-Fact | 10 Nov 2025 | 0001742485 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BBIO | Common Stock | Sale | -$791K | -12.6K | -0.27% | $62.91 | 4.63M | 06 Nov 2025 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | F1, F2, F3 |
| transaction | BBIO | Common Stock | Sale | -$465K | -7.32K | -0.16% | $63.55 | 4.62M | 06 Nov 2025 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | F1, F3, F4 |
| transaction | BBIO | Common Stock | Sale | -$6.44K | -100 | 0% | $64.39 | 4.62M | 06 Nov 2025 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | F1, F3 |
| transaction | BBIO | Common Stock | Sale | -$764K | -12.5K | -0.27% | $61.14 | 4.61M | 07 Nov 2025 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | F1, F3, F5 |
| transaction | BBIO | Common Stock | Sale | -$452K | -7.31K | -0.16% | $61.87 | 4.6M | 07 Nov 2025 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | F1, F3, F6 |
| transaction | BBIO | Common Stock | Sale | -$12.6K | -200 | 0% | $62.81 | 4.6M | 07 Nov 2025 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | F1, F3, F7 |
| transaction | BBIO | Common Stock | Sale | -$788K | -12.5K | -1.5% | $62.91 | 823K | 06 Nov 2025 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | F1, F2, F3 |
| transaction | BBIO | Common Stock | Sale | -$468K | -7.37K | -0.9% | $63.56 | 816K | 06 Nov 2025 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | F1, F3, F4 |
| transaction | BBIO | Common Stock | Sale | -$6.44K | -100 | -0.01% | $64.39 | 816K | 06 Nov 2025 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | F1, F3 |
| transaction | BBIO | Common Stock | Sale | -$748K | -12.2K | -1.5% | $61.13 | 803K | 07 Nov 2025 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | F1, F3, F8 |
| transaction | BBIO | Common Stock | Sale | -$467K | -7.55K | -0.94% | $61.87 | 796K | 07 Nov 2025 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | F1, F3, F9 |
| transaction | BBIO | Common Stock | Sale | -$13.8K | -220 | -0.03% | $62.79 | 796K | 07 Nov 2025 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | F1, F3, F10 |
| holding | BBIO | Common Stock | 223K | 06 Nov 2025 | Direct |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. |
| F2 | Represents the weighted average sale price of the shares sold from $62.245 to $63.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F3 | The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| F4 | Represents the weighted average sale price of the shares sold from $63.25 to $64.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F5 | Represents the weighted average sale price of the shares sold from $60.59 to $61.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F6 | Represents the weighted average sale price of the shares sold from $61.59 to $62.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F7 | Represents the weighted average sale price of the shares sold from $62.78 to $62.83 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F8 | Represents the weighted average sale price of the shares sold from $60.57 to $61.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F9 | Represents the weighted average sale price of the shares sold from $61.58 to $62.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F10 | Represents the weighted average sale price of the shares sold from $62.68 to $62.83 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |